ClinicalTrials.gg
CompletedNCT04594161STONEUpdated Feb 28, 2024

Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis

An interventional study of Percutaneous Nephrostomy and Double J catheter in Urolithiasis, Urologic Diseases and Urinary Calculi, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Completed at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2024-02-28.

Primary conditionKidney CalculiRegistry: UrolithiasisReclassifiedWhy we changed it
Registry
Urolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Calculi
Why
  1. The study's listed conditions name Kidney Calculi, a narrower term within Urolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Sex
All
01

Study summary

To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or kidney function deterioration) caused by urolithiasis.

Read the detailed description

SUMMARY Rationale If a stone obstructs the ureter and impairs urine-efflux from the kidney this may cause infection, pain resulting from a renal colic and/or renal impairment. Drainage of the kidney may be necessary and can be established by placement of either a percutaneous nephrostomy (PCN) or a retrograde double J catheter (JJ). Considering method of drainage, setting, room in which drainage procedures takes place and anesthesia method, there are in fact 16 different approaches for drainage available, each with its own consequences for the patient and on expenses. Although evidence is poor, both methods of drainage are to be considered as equal.[1] This is reflected by the differences in preference between different countries.[2] In 2016 the Dutch association for urology (Nederlandse Vereniging voor Urologie (NVU)) marked this subject as one of the primary knowledge gaps in urology in The Netherlands and gave it priority on the national knowledge agenda for urology.[3] From patients' as well as from societal perspective it is of importance that the decision for placement of either PCN or JJ will be made based on evidence based arguments and in a uniform way.

Hypothesis: Percutaneous nephrostomy is non inferior to retrograde double J catheter regarding time to clinical recovery. Secondly, patient reported outcome measures (PROMS) comparing treatment room and OR settings of drainage procedures will most likely not be significantly different.

Finally, because percutaneous nephrostomy catheters are more often placed in a (outpatient) urological or radiological treatment room, this is expected to be less expensive than placement of a double J catheter (more often placed in the OR). Objective: To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or kidney function deterioration) caused by urolithiasis.

Study design: Multicenter prospective randomized controlled non-inferiority trial.

Study population: Male and female adult patients with signs of obstructive kidney disease with kidney or ureteral lithiasis as an underlying cause and with an indication for drainage based on symptoms of or laboratory tests indicating infection and/or pain and/or kidney function.

Intervention: One group receives drainage by percutaneous nephrostomy catheter placement as opposed to the other group which will receive drainage by retrograde double J catheter placement.

Main study parameters/endpoints:

The primary objective is to assess whether a PCN is non-inferior to double J catheter regarding time to clinical recovery in patients with obstructive kidney disease resulting from urolithiasis.

The primary outcome parameter is time to clinical recovery. Clinical recovery is defined as reaching one or more of the following criteria. The mandatory amount of criteria to achieve clinical recovery is dependent on the indication for placement of a PCN or a JJ.

  • If indication for drainage is infection: improvement of infection, indicated by a decrease of WBC in two executive laboratory results and below 15.000 mm3 and a body temperature of 36-38.5 C. and/or
  • If indication for drainage is untreatable pain: Numeric rating score (NRS) considering pain resulting from a renal colic is improved and \< 3 points and/or
  • If indication for drainage is deterioration of kidney function: improvement of creatinine/ Glomerular Filtration Rate (GFR) in two executive laboratory results It may occur that the indication for drainage is a combination of the above named indications. Clinical recovery will then be reached in case all parameters related to the different indications are within the set range. Secondary outcomes are further clinical data, PROMS (measured by the EQ-5D-5L, NRS, a satisfaction scale and a catheter questionnaire) and societal costs (measured by a diseasespecified iMCQ questionnaire).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The placement of either PCN or double J catheter is standard care. Currently the choice for PCN or a double J catheter is based on expert opinion and may be driven by arguments considering logistics or assumptions about the quality of life for a patient after placement.

Considering the difference in rate of placement of both PCN and double J catheter between various hospitals and different countries, it is believed experts have no uniform work method to handle the dilemma of choosing between these two techniques.[2] Furthermore the current EAU-guideline 2018 states that both methods of drainage are to be considered as equal.[1] Therefore there is no reason to believe, patients will be affected negatively by being placed randomly in either the double J group or the PCN group. Questionnaires will be filled in daily during hospitalization and twice or less afterwards. This is not considered to be a risk for the patient. The longest questionnaires (EQ-5D-5L and iMCQ) will take approximately 10-20 minutes to fill in, additional to the shorter scales (NRS, satisfaction scale) which will take approximately 1 minute to fill in. Generally It will take 90 minutes, spread over the course of three months, to fill in all questionnaires. For frequency and timing of the questionnaires. Finally, no additional visits to a hospital, withdrawal of blood samples or exposure to radiation is to be expected when taking part in this study.

02

Conditions studied

  • Urolithiasis
  • Urologic Diseases
  • Urinary Calculi
  • Urinary Obstruction
  • Urinary Stone
  • Ureteric Obstruction
  • Calculus Ureteral
  • Stone Ureter
  • Stone;Renal
  • Stone, Kidney
  • Stone, Urinary
  • Obstruction Ureter
  • Obstruction
  • Ureter Calculi
  • Ureter Obstruction
  • Kidney Diseases
  • Kidney Calculi
  • Kidney Failure, Acute
  • Kidney Dysfunction
  • Kidney Insufficiency
  • Pyelonephritis
  • Pyelonephritis Acute
  • Pyelonephritis Obstructive
  • Pyelonephritis; Calculus
  • Pyelonephritis; Obstruction
  • Pyelonephrosis
  • Hydronephrosis
  • Hydronephrosis; Infection
  • Hydronephrosis, Infected
  • Hydronephrosis; Obstruction, Ureter
  • Hydronephrosis; Obstruction, Renal Calculus
  • Hydronephrosis, Secondary
  • Renal Pelvis; Obstruction

Keywords

  • Urolithiasis
  • Urologic Diseases
  • Urinary Calculi
  • Urinary Obstruction
  • Urinary Stone
  • Nephrostomy; Complications
  • Catheter Complications
  • double j catheter
  • JJ catheter
  • urinary stent
  • percutaneous nephrostomy
  • stent
03

In context

Kidney Calculi Reclassified

509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.

This study's enrollment of 204 is above the median of 86 across 391 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 532 studies on the registry; 183 are open to participants now.

Compared within Kidney Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In order to be considered eligible to participate in this study, a subject must meet all of the following criteria:
  • Male/female >18 year
  • Symptoms and/or laboratory results indicating obstructive kidney disease with or without infection.
  • A kidney or ureteral stone is present on ultrasound or CT (max 3 months old prior to presentation)
  • Both drainage techniques are feasible and safe in opinion of the treating physician (from logistics point of view and in the best interest of the patient).
  • Willing and able to comply with filling in questionnaires and follow-up regiment

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Analphabetic or not mastering the Dutch language
  • Pregnancy
  • Usage of anticoagulation agents other than acetylsalicylic acid.
  • for either technique looking at history and anatomy (e.g. kidney transplant, pouch, Bricker deviation, urethral or ureteral stenosis)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Active comparator
    Percutaneous Nephrostomy

    drainage of the kidney by means of a percutaneous Nephrostomy

    Device: Percutaneous Nephrostomy

  • Active comparator
    Double J catheter

    drainage of the kidney by means of a double J catheter

    Device: Double J catheter

Interventions

  • DevicePercutaneous Nephrostomy

    A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis

    Also known as: PCN, Nephrostomies, Percutaneous, Percutaneous Nephrostomies, Nephrostomy

  • DeviceDouble J catheter

    A Double J catheter will be placed in patients with obstructive urolithiasis

    Also known as: stent, JJ, internal stent, JJ catheter, urinary stent, internal urinary stent, ureteral stent, internal ureteral stent, internal ureteric stent, ureteric stent, ureteral stents, internal ureteral stents, internal ureteric stents, ureteric stents, double j ureteral catheter, double-j catheter, internalized double-j catheter

06

What researchers measure

Primary outcomes

  1. time (hours) to clinical recovery regarding infection

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately) - If indication for drainage is infection clinical recovery is defined as: improvement of infection, indicated by a decrease of WBC (unit: mm3) in two executive laboratory results and at least below 15.000 mm3.

    Time frame: 3 months

  2. time (hours) to clinical recovery regarding infection

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately) - If indication for drainage is infection clinical recovery is defined as: improvement of infection, indicated by a body temperatur between 36.0-38.5 °Celsius. and/or * If indication for drainage is untreatable pain: Numeric rating score (NRS) considering pain resulting from a renal colic is improved and \< 3 points and/or * If indication for drainage is deterioration of kidney function: improvement of creatinine/ Glomerular Filtration Rate (GFR) in two executive laboratory results

    Time frame: 3 months

  3. time (hours) to clinical recovery regarding pain

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately) If indication for drainage is untreatable pain clinical recover is defined as: Numeric Rating Score (NRS) considering pain resulting from a renal colic is improved and \< 3 points (higher scores mean greater level of pain).

    Time frame: 3 months

  4. time (in hours) to clinical recovery regarding kidney function

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately) If indication for drainage is deterioration of kidney function: improvement of creatinine (μmol/L) and/or Glomerular Filtration Rate (ml/min/1.73 m2) in two executive laboratory results.

    Time frame: 3 months

Secondary outcomes

  1. patient reported outcome measures (PROMS) quality of life

    EQ-5D-5L questionnaire (range 0-1; greater scores reflect a higher quality of life).

    Time frame: 3 months

  2. patient reported outcome measures (PROMS) pain score

    Numeric Rating Score (NRS) considering pain questionnaire (range 0-10; greater scores reflect higher pain levels)

    Time frame: 3 months

  3. patient reported outcome measures (PROMS) satisfaction

    satisfaction scale (range 0-10; greater scores reflect higher levels of satisfaction)

    Time frame: 3 months

  4. patient reported outcome measures (PROMS) catheter related problems

    catheter questionnaire. All answers will be analysed using frequencies. No score is applicable.

    Time frame: 3 months

  5. patient reported outcome measures (PROMS) cost and productivity

    disease-specified iMCQ (Medical Consumption Questionnaire)/iPCQ (Productivity Cost Questionnaire). All answers will be analyzed using frequencies and will be used in economical models to calculate productivity burden and societal and individual costs.

    Time frame: 3 months

  6. patient reported outcome measures (PROMS) on costs iMCQ (Medical consumption questionnaire)

    disease-specified iMCQ (Medical Consumption Questionnaire). All answers will be analyzed using frequencies and will be used in economical models to calculate productivity burden and societal and individual costs.

    Time frame: 3 months

  7. patient reported outcome measures (PROMS) productivity

    iPCQ (Productivity Cost Questionnaire). All answers will be analyzed using frequencies and will be used in economical models to calculate productivity burden and societal and individual costs.

    Time frame: 3 months

07

Study locations

1 site
  • Amsterdam UMC, location AMC
    Amsterdam, Noord Holland 1105 AZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jan 2024, 41 months.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's 41 months is above that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2020
First posted
Oct 20, 2020
StartActual
Jul 15, 2020
Primary completionActual
Jan 1, 2024
CompletionActual
Jan 1, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04594161
Collaborators
Alrijne Hospital
Responsible party
Prof.dr. H.P. Beerlage (Professor doctor H.P. Beerlage, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Oct 20, 2020
Start date
Jul 15, 2020
Primary completion
Jan 1, 2024
Completion
Jan 1, 2024
Last update
Feb 28, 2024

Study contacts

Ad Hendrikx, dr.
study chair · no affiliation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion